Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Capital Expenditures (2024 - 2025)

CG Oncology (CGON) has disclosed Capital Expenditures for 2 consecutive years, with $7000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 96.65% year-over-year to $7000.0, compared with a TTM value of $134000.0 through Dec 2025, down 42.74%, and an annual FY2025 reading of $134000.0, down 42.74% over the prior year.
  • Capital Expenditures was $7000.0 for Q4 2025 at CG Oncology, down from $97000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $209000.0 in Q4 2024 and bottomed at -$1000.0 in Q3 2024.